These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23251769)

  • 21. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG; Elisaf MS
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and cost-efficiency of phosphate binders in hemodialysis.
    Fröschl B; Brunner-Ziegler S; Hiebinger C; Wimmer A; Zsifkovits J
    GMS Health Technol Assess; 2009 Jun; 5():Doc08. PubMed ID: 21289895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
    Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
    Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphate binders in CKD: chalking out the differences.
    Rees L; Shroff RC
    Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M
    Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
    Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
    Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats.
    de Castro BBA; do Carmo WB; de Albuquerque Suassuna PG; Carminatti M; Brito JB; Dominguez WV; de Oliveira IB; Jorgetti V; Custodio MR; Sanders-Pinheiro H
    Exp Biol Med (Maywood); 2018 May; 243(9):796-802. PubMed ID: 29763365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data.
    Frazão JM; Adragão T
    Kidney Int Suppl; 2008 Dec; (111):S38-43. PubMed ID: 19034324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
    Terai K; Nara H; Takakura K; Mizukami K; Sanagi M; Fukushima S; Fujimori A; Itoh H; Okada M
    Br J Pharmacol; 2009 Apr; 156(8):1267-78. PubMed ID: 19302594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
    Cozzolino M; Brancaccio D
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.
    Locatelli F; Cannata-Andía JB; Drüeke TB; Hörl WH; Fouque D; Heimburger O; Ritz E
    Nephrol Dial Transplant; 2002 May; 17(5):723-31. PubMed ID: 11981055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease.
    Spasovski G
    Recent Pat Cardiovasc Drug Discov; 2008 Nov; 3(3):222-8. PubMed ID: 18991797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.